a hrefhttps:www.fiercepharma.compharmadespite-decent-data-verastem-rethinks-options-approved-oncology-combo-pancreatic-cancer hreflangenDespite decent data, Verastem rethinks options for approved oncology combo in pancreatic cancera

With good-but-not-great updated data on its approved oncology combo of avutometinib plus defactinib in first-line metastatic pancreatic cancer, Verastem Oncology will now channel its primary RampD efforts toward other pipeline darlings.